Vesical Imaging‐Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle‐invasive bladder cancer
2023; Wiley; Volume: 133; Issue: 2 Linguagem: Inglês
10.1111/bju.16191
ISSN1464-410X
AutoresAndrea Necchi, Giuseppe Basile, Ewan A. Gibb, Daniele Raggi, Giuseppina Calareso, Tiago Costa de Pádua, Damiano Alfio Patanè, Emanuele Crupi, Chiara Mercinelli, Antonio Cigliola, Valentina Tateo, Patrizia Giannatempo, Marco Moschini, Alberto Briganti, Francesco Montorsi, A. Messina, Jeffrey S. Ross, Dean C. Pavlick, Francesco De Cobelli, Giorgio Brembilla,
Tópico(s)Cancer Immunotherapy and Biomarkers
ResumoTo evaluate the predictive capability of the pre- and post-pembrolizumab Vesical Imaging-Reporting and Data System (VI-RADS) to identify ypT0N0 or ypT≤1N0 response in muscle-invasive bladder cancer (MIBC) within the PURE-01 trial (ClinicalTrials.gov identifier: NCT02736266).
Referência(s)